Cargando…
P264 Brain phaeohyphomycosis secondary to immunosuppressant therapy due to Rhinocladiella mackenziei
POSTER SESSION 2, SEPTEMBER 22, 2022, 12:30 PM - 1:30 PM: : Two cases of Rhinocladiella mackenziei have been noted in our institute, the first case in 2015 (post-renal transplant) and the second case in 2021 (post-COVID infection). Both the patients had received immunosuppressants for varying dur...
Autores principales: | Rai, Madhu, Patel, Medical Priyanka, Rodriguez, Camilla, Basu, Shaoli, Salvi, Asmita, Agrawal, Umang, Sunavala, Ayesha, Soman, Rajiv, Shetty, Anjali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516185/ http://dx.doi.org/10.1093/mmy/myac072.P264 |
Ejemplares similares
-
Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei in an immunocompetent patient: A case report and review of literature
por: Zain Mushtaq, Muhammad, et al.
Publicado: (2020) -
Morocco as a possible source for acquisition of Rhinocladiella mackenziei
por: Lafont Rapnouil, Baptiste, et al.
Publicado: (2021) -
P265 Phaeohyphomycosis caused by Rhinocladiella similis mimicking Sporotrichosis
por: Taneja, Juhi, et al.
Publicado: (2022) -
Post-COVID-19 Cerebral Pheohyphomycosis due to Rhinocladiella mackenziei: A Middle Eastern Replica of Post-COVID-19 Mucormycosis?
por: Wankhade, Bhushan Sudhakar, et al.
Publicado: (2022) -
P154 Fungal spore count in a tertiary care hospital in Mumbai, India
por: Naik, Aparna, et al.
Publicado: (2022)